Evaluation of antitumour effects of docetaxel (Taxotere®) on human gastric cancers in vitro and in vivo

European Journal of Cancer

Volumn 32, Issue 2, 1996, Pages 226-230

  Tanaka, M ^a   Obata, T ^a   Sasaki, T ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Antitumour effect; Docetaxel; Gastric cancer

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PIRARUBICIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CULTURE; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PACLITAXEL; STOMACH NEOPLASMS; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0029996299     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00500-5     Document Type: Article

References (25)

1. Ringel I, Horwitz SB. Studies with RP 56976 (docetaxel): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991, 83, 288-291.
2. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichometry, and competition. Biochemistry 1993, 32, 2747-2755.
3. Schiff PB, Horwitz SB. Taxol stabilized microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980, 77, 1561-1565.
4. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991, 51, 4845-4852.
5. Harrison SD, Dykes DJ, Bissery MC, Griswold DP. Response of four human tumor xenografts in nude mice to taxotere. 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy 1992, Abstract no. 251, 121.
6. Grem JL, Tutsch KD, Simson KJ, et al. Phase I study of taxol administered as a short iv infusion daily for 5 days. Cancer Treat Rep 1987, 71, 1179-1184.
7. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of taxotere: five-day schedule. J Natl Cancer Inst 1992, 84, 1781-1788.
8. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol®) and docetaxel (Taxotere®). Cancer Treat Rev 1993, 19, 351-386.
9. Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD. Effect of taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 1992, 3, 121-124.
10. Riou JF, Naudin A, Lavelle F. Effect of taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 1992, 187, 164-170.
11. Vogel M, Hilsenbeck SG, Depenbrock H, et al. Preclinical activity of taxotere (RP56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer 1993, 29, 2009-2014.
12. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987, 47, 936-942.
13. Furukawa T, Kubota T, Watanabe M, et al. High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int Natl J Cancer 1992, 51, 489-498.
14. Ohyama S, Tanaka M, Yonemura Y, Kinoshita K, Miyazaki I, Sasaki T. In vitro chemosensitivity test of gastric carcinomas using collagen gel matrix. Jpn J Cancer Res 1991, 82, 607-612.
15. Egawa M, Hisazumi H, Uchibayashi T, Tanaka M, Sasaki, T. Comparative study of 3-(4,5-dimethylthiazol-2-yl)-2,5,-diphenyl-tetrazolium bromide and tritiated thymidine in a chemosensitivity test using collagen gel matrix. Urological Res 1993, 21, 83-88.
16. Taguchi T, Furue H, Niitani H, et al. Phase 1 clinical trial of RP 56976 (docetaxel) a new anticancer drug. Jpn J Cancer Chemother 1994, 21, 1997-2005.
17. Horikoshi N, Inoue K, Aiba K, et al. Phase I study of paclitaxel. Jpn J Cancer Chemother 1994, 21, 2407-2414.
18. Scheithauer W, Clark GM, Salmon SE, Dorda W, Shoemaker RH, Von Hoff DD. Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep 1986, 70, 1379-1382.
19. Ovejera AA, Houchens DP, Baker AD. Chemotherapy of human tumor xenografts in genetically athymic nude mice. Ann Clin Lab Sci 1978, 8, 50-56.
20. Rowinsky EK, Cazenave LA, Donehover RC. A novel investigational antimicrotubule agent. J Natl Cancer Inst 1990, 82, 1247-1259.
21. Csuka O, Sugar J, Palyi I, Somfai-Relle S. The mode of action of vinca alkaloids. Oncology 1980, 37 (Suppl. 1), 83-87.
22. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P. Relationship between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991, 34, 992-998.
23. Phillips RM, Bibby MC, Double JA. A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Natl Cancer Inst 1990, 82, 1457-1468.
24. Kubota T, Furukawa T, Kitajima M. High clinical predictability of histoculture drug response assay for drug-sensitivity of cancer of the digestive organs. Jpn J Cancer Chemother 1993, 20, 461-466.
25. Taguchi T. An early phase II clinical study of RP 56976 (docetaxel) in patients with cancer of the gastrointestinal tract. Jpn J Cancer Chemother 1994, 21, 2431-2437.